LY294002 enhances cytotoxicity of temozolomide in glioma by down-regulation of the PI3K/Akt pathway

Molecular Medicine Reports

Volumn 5, Issue 2, 2012, Pages 575-579

  Chen, Lingchao ^a   Han, Lei ^b,c   Shi, Zhendong ^b,c   Zhang, Kailiang ^b,c   Liu, Yanwei ^d   Zheng, Yongri ^a   Jiang, Tao ^d   Pu, Peiyu ^b,c   Jiang, Chuanlu ^a   Kang, Chunsheng ^b,c  

^a HARBIN MEDICAL UNIVERSITY   (China)

^b TIANJIN MEDICAL UNIVERSITY   (China)

^c BEIJING UNIVERSITY OF POSTS AND TELECOMMUNICATIONS   (China)

^d CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

Akt; Glioma; LY294002; Temozolomide

Indexed keywords

2 MORPHOLINO 8 PHENYLCHROMONE; CASPASE 3; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; TEMOZOLOMIDE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER INVASION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG SCREENING; ENZYME PHOSPHORYLATION; GLIOBLASTOMA; HUMAN; HUMAN CELL; PROTEIN EXPRESSION; UPREGULATION;

ANTINEOPLASTIC AGENTS, ALKYLATING; BCL-2-ASSOCIATED X PROTEIN; CASPASE 3; CELL LINE, TUMOR; CHROMONES; DACARBAZINE; DOWN-REGULATION; DRUG SYNERGISM; GLIOMA; HUMANS; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; SIGNAL TRANSDUCTION;

ATAXIA TELANGIECTASIA;

EID: 84862931549     PISSN: 17912997     EISSN: 17913004     Source Type: Journal    
DOI: 10.3892/mmr.2011.674     Document Type: Article

References (26)

1. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY and Olson JJ: Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin 60: 166.193, 2010.
2. Stupp R, Mason WP, van den Bent MJ, et al: Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996, 2005. (Pubitemid 40349501)
3. Butowski NA, Sneed PK and Chang SM: Diagnosis and treatment of recurrent high-grade astrocytoma. J Clin Oncol 24: 1273-1280, 2006. (Pubitemid 46622030)
4. Kamiryo T, Tada K, Shiraishi S, Shinojima N, Kochi M and Ushio Y: Correlation between promoter hypermethylation of the O6-methylguanine- deoxyribonucleic acid methyltransferase gene and prognosis in patients with high-grade astrocytic tumors treated with surgery, radiotherapy, and 1-(4-amino-2-methyl-5-pyrimidinyl)methyl-3-(2-chloroethyl)-3-nitrosourea-based chemotherapy. Neurosurgery 54: 349-357, 2004. (Pubitemid 38209403)
5. Verhaak RG, Hoadley KA, Purdom E, et al: Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110, 2010.
6. Noushmehr H, Weisenberger DJ, Diefes K, et al: Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma. Cancer Cell 17: 510-522, 2010.
7. Bredel M, Scholtens DM, Harsh GR, et al: A network model of a cooperative genetic landscape in brain tumors. JAMA 302: 261-275, 2009.
8. Brennan C, Momota H, Hambardzumyan D, et al: Glioblastoma subclasses can be defined by activity among signal transduction pathways and associated genomic alterations. PLoS One 4: e7752, 2009.
9. Brennan C, Momota H, Hambardzumyan D, et al: β-secretase inhibitors enhance temozolomide treatment of human gliomas by inhibiting neurosphere repopulation and xenograft recurrence. Cancer Res 70: 6870-6879, 2011.
10. Sunayama J, Sato A, Matsuda K, et al: Dual blocking of mTor and PI3K elicits a prodifferentiation effect on glioblastoma stem-like cells. Neuro Oncol 12: 1205-1219, 2011.
11. Cloughesy TF and Mischel PS: New strategies in the molecular targeting of glioblastoma: how do you hit a moving target? Clin Cancer Res 17: 6-11, 2010.
12. Chamberlain MC: Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. Expert Rev Neurother 10: 1537-1544, 2010.
13. Roos WP, Batista LF, Naumann SC, et al: Apoptosis in malignant glioma cells triggered by the temozolomide-induced DNA lesion O6-methylguanine. Oncogene 26: 186-197, 2007. (Pubitemid 46095730)
14. Sarkaria JN, Kitange GJ, James CD, et al: Mechanisms of chemoresistance to alkylating agents in malignant glioma. Clin Cancer Res 14: 2900-2908, 2008.
15. Dinnes J, Cave C, Huang S and Milne R: A rapid and systematic review of the effectiveness of temozolomide for the treatment of recurrent malignant glioma. Br J Cancer 86: 501-505, 2002. (Pubitemid 34185082)
16. Friedman HS, Kerby T and Calvert H: Temozolomide and treatment of malignant glioma. Clin Cancer Res 6: 2585-2597, 2000. (Pubitemid 30482092)
17. Chang SM, Theodosopoulos P, Lamborn K, et al: Temozolomide in the treatment of recurrent malignant glioma. Cancer 100: 605-611, 2004. (Pubitemid 38124780)
18. Kubiatowski T, Jang T, Lachyankar MB, et al: Association of increased phosphatidylinositol 3-kinase signaling with increased invasiveness and gelatinase activity in malignant gliomas. J Neurosurg 95: 480-488, 2001. (Pubitemid 32781501)
19. Shin JY, Kim JO, Lee SK, Chae HS and Kang JH: LY294002 may overcome 5-FU resistance via down-regulation of activated p-Akt in Epstein-Barr virus-positive gastric cancer cells. BMC Cancer 10: 425, 2010.
20. Ikezoe T, Nishioka C, Bandobashi K, et al: Longitudinal inhibition of PI3K/Akt/mTOR signaling by LY294002 and rapamycin induces growth arrest of adult T-cell leukemia cells. Leuk Res 31: 673-682, 2007. (Pubitemid 46560001)
21. Stupp R, Gander M, Leyvraz S, Newlands E: Current and future developments in the use of temozolomide for the treatment of brain tumours. Lancet Oncol 2: 552-560, 2001. (Pubitemid 33586868)
22. Nagane M, Coufal F, Lin H, Bogler O, Cavenee WK and Huang HJ: A common mutant epidermal growth factor receptor confers enhanced tumorigenicity on human glioblastoma cells by increasing proliferation and reducing apoptosis. Cancer Res 56: 5079-5086, 1996. (Pubitemid 26374452)
23. Weller M, Malipiero U, Aguzzi A, Reed JC and Fontana A: Protooncogene bcl-2 gene transfer abrogates Fas/APO-1 antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic drugs and therapeutic irradiation. J Clin Invest 95: 2633-2643, 1995.
24. Caporali S, Levati L, Starace G, et al: AKT is activated in an ataxia-telangiectasia and Rad3-related-dependent manner in response to temozolomide and confers protection against drug-induced cell growth inhibition. Mol Pharmacol 74: 173-183, 2008. (Pubitemid 351872168)
25. Opel D, Westhoff MA, Bender A, Braun V, Debatin KM and Fulda S: Phosphatidylinositol 3-kinase inhibition broadly sensitizes glioblastoma cells to death receptor- and drug-induced apoptosis. Cancer Res 68: 6271-6280, 2008.
26. Han L, Yang Y, Yue X, et al: Inactivation of PI3K/AKT signaling inhibits glioma cell growth through modulation of β-catenin-mediated transcription. Brain Res 1366: 9-17, 2010.